Snehal Gis: Gene Therapy Revolutionizing the Hemophilia Treatment Landscape
Snehal Gis, Senior Digital Analyst Manager and Senior Research Associate at Global Insight Services shared a post on LinkedIn:
”The Hemophilia Gene Therapy Market is entering a transformative phase, driven by the promise of long-term or potentially curative treatments for patients suffering from hemophilia, a rare genetic bleeding disorder.
Unlike traditional therapies that rely on frequent factor replacement infusions, gene therapy introduces functional copies of defective genes into a patient’s cells, enabling the body to produce clotting factors naturally.
This shift represents a paradigm change in treatment approaches, offering improved quality of life and reduced lifetime healthcare costs.
Click to Request a Sample of this Report for Additional Market Insights.”
Stay updated with Hemostasis Today.
-
Jun 28, 2026, 19:05Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
-
Jun 28, 2026, 19:05Pinar Demirtepe: Not All “Blood Thinners” Are the Same
-
Jun 28, 2026, 19:05Andrea Cesari: Comparing Catheter-Based Reperfusion Strategies for Intermediate-High-Risk PE
-
Jun 28, 2026, 19:02Nassim Emteir: Interpreting TSAT with Ferritin to Guide Iron Deficiency Diagnosis and Treatment
-
Jun 28, 2026, 19:00Andrew Jackson: Predicting PICC-Related Venous Thrombosis in Patients Undergoing Radiotherapy
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients